Home › Follicular Lymphoma › Maryland › Baltimore
Follicular Lymphoma clinical trials in Baltimore, MD
4 studies for Follicular Lymphoma are looking for participants at sites in and around Baltimore (within about 30 miles). Open a study to see who can join and how to contact the study team.
Recruiting for a study here? Feature it at the top of this page — $99 for 30 days →
A Study of Surovatamig (AZD0486) Plus Rituximab in Previously Untreated Follicular Lymphoma Patients
RecruitingPhase 3
- Research Site, Baltimore
A Study to Compare the Efficacy and Safety of Golcadomide in Combination With Rituximab (Golca + R) vs Investigator's Choice in Participants With Relapsed/Refractory Follicular Lymphoma Who Have Received at Least 1 Prior Line of Systemic Therapy (GOLSEEK-4)
RecruitingPhase 3
- Local Institution - 0023, Baltimore
- Greater Baltimore Medical Center, Towson · 8 mi away
AS-1763 in Patients With Previously Treated CLL/SLL or Non-Hodgkin Lymphoma
RecruitingPhase 1
- University of Maryland Medical Center - Greenebaum Comprehensive Cancer Center, Baltimore
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
RecruitingObservational study
- Massive Bio SYNERGY-AI site, Baltimore
- Massive Bio SYNERGY-AI site, Towson · 8 mi away
Follicular Lymphoma trials in other cities
- New York City, NY24 studies
- Milwaukee, WI19 studies
- Nashville, TN18 studies
- Houston, TX18 studies
- Boston, MA17 studies
- Baldwin Park, CA16 studies
- Seattle, WA15 studies
- Durham, NC15 studies
- Columbus, OH13 studies
- Salt Lake City, UT13 studies
- Philadelphia, PA12 studies
- Chicago, IL12 studies
Other studies in Baltimore
- Non-Small Cell Lung Cancer60 studies
- Breast Cancer47 studies
- Prostate Cancer43 studies
- Lung Cancer40 studies
- Cancer (all types)37 studies
- Colorectal Cancer31 studies
- Pancreatic Cancer31 studies
- Metastatic Cancer28 studies
- Obesity25 studies
- Heart Failure24 studies
- Bladder Cancer24 studies
- Stroke22 studies
From ClinicalTrials.gov, data retrieved Oct 5, 2026. Each study sets its own eligibility; the study team decides who can join.